Wedbush Analysts Raise Earnings Estimates for VRDN

Key Points

• Wedbush raised its Q3 2025 EPS estimate for Viridian Therapeutics from ($0.78) to ($0.13), reflecting improved earnings expectations.
• Viridian's current full-year earnings consensus estimate stands at ($4.03) per share, with projections indicating declining losses through FY2026.
• Several analysts issued adjusted price targets for Viridian Therapeutics, with Oppenheimer increasing theirs from $28.00 to $32.00 and Goldman Sachs raising theirs from $27.00 to $30.00.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Analysts at Wedbush upped their Q3 2025 earnings per share estimates for Viridian Therapeutics in a report released on Wednesday, August 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.78). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics' Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($3.27) EPS, FY2027 earnings at ($1.07) EPS and FY2029 earnings at $7.23 EPS.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, meeting analysts' consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. During the same quarter in the previous year, the business earned ($0.81) earnings per share. The company's revenue for the quarter was up 4.2% on a year-over-year basis.

Several other research firms also recently issued reports on VRDN. The Goldman Sachs Group boosted their price objective on Viridian Therapeutics from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, August 7th. JMP Securities cut their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Oppenheimer boosted their price objective on Viridian Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Needham & Company LLC cut their price objective on Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Finally, Wells Fargo & Company lowered their target price on Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $37.00.

Viridian Therapeutics Trading Up 4.7%

NASDAQ:VRDN traded up $0.84 on Monday, reaching $18.81. The company's stock had a trading volume of 576,633 shares, compared to its average volume of 895,461. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $27.20. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -4.94 and a beta of 0.42. The stock has a 50 day moving average price of $16.08 and a 200 day moving average price of $15.18.

Institutional Trading of Viridian Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank raised its stake in shares of Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after buying an additional 840 shares in the last quarter. Foresite Capital Management VI LLC purchased a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $38,000. GAMMA Investing LLC raised its stake in shares of Viridian Therapeutics by 3,892.9% during the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock worth $114,000 after buying an additional 8,214 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after buying an additional 1,516 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Viridian Therapeutics during the 2nd quarter worth approximately $170,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.